What is Minomic?
Minomic is dedicated to advancing cancer diagnostics through the development and commercialization of novel tests for solid tumors, with a particular focus on prostate, bladder, and pancreatic cancers. Their flagship product, MiCheck® Prostate, is a blood test available in the US and Australia. This test leverages a patented monoclonal antibody and other biomarkers to generate a clinically significant risk score for prostate cancer, aiding urologists in making informed biopsy decisions. The company's strategy is built upon a comprehensive intellectual property portfolio and strategic collaborations to enhance patient outcomes.
How much funding has Minomic raised?
Minomic has raised a total of $3.7M across 1 funding round:
Private Equity
$3.7M
Private Equity (2016): $3.7M, investors not publicly disclosed
What's next for Minomic?
The substantial enterprise-level funding, including the recent strategic investment, positions Minomic for significant scaling and further development of its diagnostic pipeline. This capital infusion is expected to accelerate the commercialization of MiCheck® Prostate and support the advancement of tests for other critical cancers like bladder and pancreatic. Minomic's focus on improving patient outcomes through precise diagnostics suggests a trajectory towards broader market penetration and potential strategic partnerships within the healthcare and biotechnology sectors.
See full Minomic company page
